Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 42,692 |
|
|||||
| News | - | ||||||
| Day High | 0.666399 | Low High |
|||||
| Day Low | 0.6527 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Compugen Ltd | CGEN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.012 | -1.79% | 0.657 | 11:40:36 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.66 | 0.6527 | 0.666399 | 0.669 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 96 | 42,692 | $ 0.6584708 | $ 28,111 | - | 0.53 - 1.4897 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:39:30 | 100 | $ 0.657 | USD |
Compugen Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 58.23M | 88.23M | - | 7.5M | -33.69M | -0.38 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Compugen News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CGEN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.64 | 0.678 | 0.62 | 0.6523553 | 150,026 | 0.017 | 2.66% |
| 1 Month | 0.7842 | 0.7905 | 0.53 | 0.6320724 | 236,624 | -0.1272 | -16.22% |
| 3 Months | 1.05 | 1.11 | 0.53 | 0.7727692 | 169,688 | -0.393 | -37.43% |
| 6 Months | 1.08 | 1.4897 | 0.53 | 1.08 | 306,902 | -0.423 | -39.17% |
| 1 Year | 1.01 | 1.4897 | 0.53 | 0.9479091 | 395,656 | -0.353 | -34.95% |
| 3 Years | 13.06 | 15.16 | 0.51 | 5.02 | 854,606 | -12.40 | -94.97% |
| 5 Years | 3.41 | 19.90 | 0.51 | 7.56 | 777,506 | -2.75 | -80.73% |
Compugen Description
| Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its innovative immuno-oncology pipeline consists of four clinical stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. |
